The goal of this collaboration is to create a kitted NGS product that will enable researchers and biopharma companies to conduct biomarker discovery work using non-invasive blood samples collected from patients in clinical trials.
By delivering comprehensive genomic insights from the samples, researchers may generate clinical data repositories to gain deep insights into the molecular evolution of tumors throughout the treatment course without the need for invasive, and resource-intensive, serial tissue biopsies.
Using DNA isolated from patient blood samples, the automated NGS solution will detect somatic alterations across more than 500 genes in cancer and drug-resistance related pathways.
The profiling assay will report single nucleotide variants, insertion/deletions, copy number alterations, rearrangements, and genomic signatures, including microsatellite instability and tumor mutation burden.
A key advantage of this solution will be the ability to provide comprehensive genomic profiling data in clinical trials where tissue is not available, and it will enable investigators to evaluate drug response dynamics and emerging mechanisms of treatment resistance.
During the development process of this new liquid biopsy biomarker discovery solution, PGDx and Eisai will provide opportunities for researchers around the globe to join the collaboration.
It is a shared goal and vision of the two companies that this solution will be utilised in clinical trials, as well as become a future standard option in clinical practice.
Personal Genome Diagnostics empowers the fight against cancer by unlocking actionable information from the genome.
We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.
PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval